Show simple item record

dc.contributor.authordeSouza, NMen_US
dc.contributor.authorLiu, Yen_US
dc.contributor.authorChiti, Aen_US
dc.contributor.authorOprea-Lager, Den_US
dc.contributor.authorGebhart, Gen_US
dc.contributor.authorVan Beers, BEen_US
dc.contributor.authorHerrmann, Ken_US
dc.contributor.authorLecouvet, FEen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2018-02-16T10:14:30Z
dc.date.available2018-02-16T10:14:30Z
dc.date.issued2018-01-10en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/29331524en_US
dc.identifierS0959-8049(17)31491-0en_US
dc.identifier.citationEur J Cancer, 2018en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1166
dc.identifier.eissn1879-0852en_US
dc.identifier.doi10.1016/j.ejca.2017.12.012en_US
dc.description.abstractPatients with oligometastatic disease (OMD) often have controllable symptoms, and cures are possible. Technical improvements in surgery and radiotherapy have introduced the option of metastasis-directed ablative therapies as an adjunct or alternative to standard-of-care systemic therapies. Several clinical trials and registries are investigating the benefit of these therapeutic approaches across several cancer sites. This requires that patients are correctly included and followed with appropriate imaging. This article discusses the evidence and offers recommendations for the implementation of standard-of-care (Response Evaluation Criteria in Solid Tumours measurements on computed tomography [CT], magnetic resonance imaging [MRI] and bone scintigraphy) and advanced imaging modalities (functional, metabolic and radionuclide targeted) for identifying and following up patients with OMD. Imaging requirements for recognising OMD vary with tumour type, metastatic location, and timing of measurement in relation to previous treatment. At each point in the disease cycle (diagnosis, response assessment and follow-up), imaging must be tailored to the clinical question and the context of prior treatment. The differential use of whole-body approaches such as 18F-FDG-positron emission tomography (PET)/CT, diffusion-weighted MRI, 18F-Choline-PET/CT and 68Ga-prostate specific membrane antigen-PET/CT require rationalisation depending on clinical risk assessment. Optimal standardised imaging approaches will enable OMD trials to document patterns of disease progression and outcomes of treatment. Quality assured and quality controlled imaging data included in databases such as the European Organisation for Research and Treatment of Cancer Imaging platform for the Oligocare trial (a prospective, large-scale observational basket study being set up to collect outcome data from patients with OMD treated with radiation therapy) will establish a large and high-quality imaging warehouse for future research.en_US
dc.languageengen_US
dc.language.isoengen_US
dc.relation.isreplacedbyinternal/1228
dc.relation.isreplacedbyhttps://repository.icr.ac.uk/handle/internal/1228
dc.subjectBreast canceren_US
dc.subjectComputed tomographyen_US
dc.subjectGastrointestinal canceren_US
dc.subjectLung canceren_US
dc.subjectMagnetic resonance imagingen_US
dc.subjectMolecular imagingen_US
dc.subjectOligometastasesen_US
dc.subjectPositron emission tomographyen_US
dc.subjectProstate canceren_US
dc.titleStrategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-12-07en_US
rioxxterms.versionofrecord10.1016/j.ejca.2017.12.012en_US
rioxxterms.licenseref.startdate2018-01-10en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfEur J Canceren_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance
pubs.publication-statusPublished onlineen_US
pubs.embargo.termsNo embargoen_US
icr.researchteamMagnetic Resonance
dc.contributor.icrauthordeSouza, Nanditaen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record